The Op­di­vo-Yer­voy com­bo from Bris­tol My­ers is work­ing to­ward ap­proval in first-line liv­er can­cer

Bris­tol My­ers Squibb is work­ing to­ward its ninth ap­proval for its Op­di­vo-Yer­voy com­bi­na­tion, this time in the first-line set­ting for ad­vanced liv­er can­cer.

In topline Phase 3 da­ta re­leased Wednes­day, the com­bi­na­tion met its pri­ma­ry end­point, over­all sur­vival, at an in­ter­im analy­sis as a first-line treat­ment for pa­tients with ad­vanced he­pa­to­cel­lu­lar car­ci­no­ma. He­pa­to­cel­lu­lar car­ci­no­ma is the most com­mon type of pri­ma­ry liv­er can­cer and ac­counts for 90% of all liv­er can­cers.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER